Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00628394 · ClinicalTrials.gov registry record · Phase 4

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

A Phase 4 study of Cognition in Schizophrenia, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
Phase 4
Development phase
119
Enrollment target
1
Study location

NCT00628394: Completed Phase 4 study of Cognition in Schizophrenia, sponsored by University of Texas Southwestern Medical Center.

NCT00628394 is a Phase 4 study of Cognition in Schizophrenia that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 119 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00628394, a Phase 4 study of Cognition in Schizophrenia, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
119 participants
Enrollment target
1
Study location

Study Summary

This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving. During this study, we will test if cognitive remediation (computer games made to improve thinking), used along with a drug called atomoxetine, may help the problems in thinking as well as some of the symptoms of schizophrenia.

Primary Outcome

Gordon Continuous Performance Test - Distractibility Version The test is designed assess a person's executive functioning by testing their ability to maintain their focus over a period of time. They are intended to respond to a series of targets or inhibit their responses to a variety of foils. They are mainly assessed for their omissions and commissions. The omission and commission errors assess the person's ability to screen out extraneous stimuli while responding correctly and inhibiting inco

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Atomoxetine

Study Locations (1)

Texas

  • The University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2003-09
Est. Completion 2011-02
Phase Phase 4

What the finished NCT00628394 record still lists

NCT00628394 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Cognition in Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00628394 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00628394 about?

NCT00628394 is a clinical study titled "Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation". This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving. During this study, we will test if cognitive remediation (computer games made to improve thinking), used along with a drug called at...

What is the current status of trial NCT00628394?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 119 participants. The study started on 2003-09. Estimated completion is 2011-02.

What conditions does trial NCT00628394 study?

This clinical trial studies the following conditions: Cognition in Schizophrenia.

What interventions are being tested in trial NCT00628394?

The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG).

Who is sponsoring clinical trial NCT00628394?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00628394 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognition in Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00628394's enrollment target sits among peer trials

119 712th of 2000 higher than 1,288 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04870762 · 119 participants · Phase 2

    Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

  • NCT05559853 · 119 participants

    Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

  • NCT06564389 · 119 participants · Phase 1

    FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

  • NCT06742801 · 119 participants · NA

    Onyx™ Liquid Embolic IDE Clinical Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00628394, the US trial registry maintained by the National Library of Medicine. NCT00628394 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.